Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Hepatitis C Market 

5.1. COVID-19 Landscape: Hepatitis C Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Hepatitis C Market, By Drug Class

8.1. Hepatitis C Market, by Drug Class, 2023-2032

8.1.1. HCV Protease Inhibitors

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. HCV Polymerase Inhibitors

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. HCV NSSA Inhibitors

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Combination Therapy

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Interferon and Antiviral

8.1.5.1. Market Revenue and Forecast (2020-2032)

8.1.6. Peginterferon alfa 2a

8.1.6.1. Market Revenue and Forecast (2020-2032)

8.1.7. Peginterferon alfa 2b

8.1.7.1. Market Revenue and Forecast (2020-2032)

8.1.8. Ribavirin

8.1.8.1. Market Revenue and Forecast (2020-2032)

8.1.9. Others

8.1.9.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Hepatitis C Market, By Distribution Channel

9.1. Hepatitis C Market, by Distribution Channel, 2023-2032

9.1.1. Hospital & Retail Pharmacies

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Online Pharmacies

9.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Hepatitis C Market, Regional Estimates and Trend Forecast

10.1. North America

10.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.1.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.1.3. U.S.

10.1.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.1.4. Rest of North America

10.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.2. Europe

10.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.2.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.2.3. UK

10.2.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.2.4. Germany

10.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.2.5. France

10.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.2.6. Rest of Europe

10.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.3. APAC

10.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.3.3. India

10.3.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.3.4. China

10.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.3.5. Japan

10.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.3.6. Rest of APAC

10.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.4. MEA

10.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.4.3. GCC

10.4.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.4.4. North Africa

10.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.4.5. South Africa

10.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.4.6. Rest of MEA

10.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.5. Latin America

10.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.5.3. Brazil

10.5.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

10.5.4. Rest of LATAM

10.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)

Chapter 11. Company Profiles

11.1. Bristol-Myers Squibb Company

11.1.1. Company Overview

11.1.2. Product Offerings

11.1.3. Financial Performance

11.1.4. Recent Initiatives

11.2. Gilead Sciences, Inc.

11.2.1. Company Overview

11.2.2. Product Offerings

11.2.3. Financial Performance

11.2.4. Recent Initiatives

11.3. Abbvie

11.3.1. Company Overview

11.3.2. Product Offerings

11.3.3. Financial Performance

11.3.4. Recent Initiatives

11.4. Kadmon Holdings Inc.

11.4.1. Company Overview

11.4.2. Product Offerings

11.4.3. Financial Performance

11.4.4. Recent Initiatives

11.5. F. Hoffmon La Roche Ltd.

11.5.1. Company Overview

11.5.2. Product Offerings

11.5.3. Financial Performance

11.5.4. Recent Initiatives

11.6. GlaxoSmithKline

11.6.1. Company Overview

11.6.2. Product Offerings

11.6.3. Financial Performance

11.6.4. Recent Initiatives

11.7. J & J

11.7.1. Company Overview

11.7.2. Product Offerings

11.7.3. Financial Performance

11.7.4. Recent Initiatives

11.8. Lupin Pharmaceuticals, Inc.

11.8.1. Company Overview

11.8.2. Product Offerings

11.8.3. Financial Performance

11.8.4. Recent Initiatives

11.9. Merck & Co., Inc.

11.9.1. Company Overview

11.9.2. Product Offerings

11.9.3. Financial Performance

11.9.4. Recent Initiatives

11.10. Teva Pharmaceuticals

11.10.1. Company Overview

11.10.2. Product Offerings

11.10.3. Financial Performance

11.10.4. Recent Initiatives

Chapter 12. Research Methodology

12.1. Primary Research

12.2. Secondary Research

12.3. Assumptions

Chapter 13. Appendix

13.1. About Us

13.2. Glossary of Terms